case_images: PMC3268143_01
case_images: Endoscopic examination reveals a 4 cm sized irregularly margined mass with intact mucosa (margin) and shallow ulcer (central) in descending colon.
case_images: jkss-82-45-g001.jpg
case_images: PMC3268143_01_jkss-82-45-g001.jpg
case_images: F1
case_images: Colonoscopy demonstrated a 4.0 cm sized-mass with shallow ulceration in the central area and irregular margin accompanied by intact mucosa (Fig. 1).
case_images: Trans-axial view (A) and coronal view (B) show a 4.0 cm sized homogeneous enhancing intra-luminal mass (arrow) in descending colon.
case_images: jkss-82-45-g002.jpg
case_images: PMC3268143_01_jkss-82-45-g002.jpg
case_images: F2
case_images: On contrast enhanced view, the mass had enhanced homogeneously in delayed phase (Fig. 2A, B).
case_images: Gross examination reveals a 3.9 x 3.8 cm sized, fungating, white to yellow colored and hard mass in descending colon. Mass involves muscularis propria.
case_images: jkss-82-45-g003.jpg
case_images: PMC3268143_01_jkss-82-45-g003.jpg
case_images: F3
case_images: The 3.9 x 3.8 cm sized mass grossly presented a fungating surface, white to yellow color and invaded muscularis propria (Fig. 3).
case_images: Tumor is composed of cytologically bland spinle cells arranged in hyaline stroma with scattered inflammatory cells. Inflammatory cells are composed of lymphocytes, histiocytes and plasma cells (A, H&E, x40; B, H&E, x400).
case_images: jkss-82-45-g004.jpg
case_images: PMC3268143_01_jkss-82-45-g004.jpg
case_images: F4
case_images: The specimens did not have celluar atypia or hyperchromatism in the cells (Fig. 4A, B).
case_images: Tumor cells stain strongly for vimentin and variably with myoid markers including smooth muscle actin, muscle-specific actin and desmin (A, vimentin, x200; B, actin, x200).
case_images: jkss-82-45-g005.jpg
case_images: PMC3268143_01_jkss-82-45-g005.jpg
case_images: F5
case_images: Immunohistochemically, tumor cells were positive for smooth muscle actin, and vimentin, and negative for desmin, CD117 (c-kit), anaplastic lymphoma kinase (ALK)-1 (Fig. 5A, B).